Albert David Ltd
NSE: ALBERTDAVD BSE: 524075
₹690.80
(2.25%)
Wed, 18 Mar 2026, 09:29 am
Market Cap3.77B
PE Ratio41.02
Dividend0.74
Health Technology
Pharmaceuticals: Major
24.5KAlbert David Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (8.7x coverage).
- Albert David's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Albert David's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Albert David is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Albert David is profitable, therefore cash runway is not a concern.
- Albert David is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (1748%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 99.1x debt.
- Albert David's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (30% vs 0.9% today).
- Albert David earns more interest than it pays, coverage of interest payments is not a concern.
- Albert David's level of debt (0.9%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Albert David board of directors is about average.
- More shares have been bought than sold by Albert David individual insiders in the past 3 months.
- Tarminder's remuneration is higher than average for companies of similar size in India.
misc
- Albert David is not covered by any analysts.
- Albert David has significant price volatility in the past 3 months.
past
- Albert David's 1-year earnings growth exceeds its 5-year average (66.8% vs 19.8%)
- Albert David's year on year earnings growth rate has been positive over the past 5 years.
- Albert David used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Albert David has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Albert David's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (66.8% vs 22.7%).
- Albert David has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Albert David's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Albert David is good value based on assets compared to the IN Pharmaceuticals industry average.
- Albert David is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Albert David is good value based on earnings compared to the India market.
- 524075 outperformed the Market in India which returned -14.5% over the past year.
- Albert David's share price is below the future cash flow value, but not at a substantial discount (< 40%).
- 524075 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- BSE:524075 is up 3.2% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524075 is up 3.2% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800